Psoriasis Risk With Immune Checkpoint Inhibitors
In this cohort study, patients with cancer treated with ICIs faced an increased risk of psoriasis. Medical professionals should be aware of the potential adverse effects of immunotherapy to ensure optimal cancer care.
Authors
- Yang Jiang (ORCID: https://orcid.org/0000-0002-9078-3453)
- I-Wen Chen (ORCID: https://orcid.org/0000-0002-8928-6417)
- Yi‐Hsien Chen (ORCID: https://orcid.org/0000-0002-7019-2357)
- Sheng-Yin To (ORCID: https://orcid.org/0009-0007-5996-2879)
- Cho‐Hao Lee (ORCID: https://orcid.org/0000-0002-6061-5168)
- Chia-Ching Hsu
- Hui-Wen Yang
- Yuan-Liang Wen
- Li-Ting Kao
Institutions
- Tri-Service General Hospital (TW)
- National Defense Medical Center (TW)
Publication Details
- Journal
- JAMA Dermatology
- Published
- 2024-11-06
- DOI
- https://doi.org/10.1001/jamadermatol.2024.4129
- Citations
- 12
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 3.39